Orexo Moves Forward with OX640 for Allergic Rhinitis
Orexo AB is making significant strides in the development of its intranasal rescue medication, OX640, specifically designed for individuals experiencing severe allergic reactions, including anaphylaxis. This advanced formulation employs a powder-based epinephrine delivery system, promising quick and effective relief for patients.
Study Overview and Goals
The latest clinical study, which is now underway, aims to assess OX640's performance in participants suffering from allergic rhinitis, commonly known as hay fever. Following positive findings from a prior phase 1 study involving healthy volunteers, where OX640 exhibited admirable absorption rates and effects akin to those of traditional intramuscular auto-injectors, Orexo is eager to push this innovative product further in clinical assessment.
Details of the New Clinical Study
This current study, referred to as OX640-002, involves 30 participants diagnosed with allergic rhinitis. The design includes a crossover format with four treatment periods. During one of these stages, a small allergen dose will be administered nasally to provoke an allergic response, subsequently evaluating OX640's efficacy against absorption from other methods, including a common intramuscular epinephrine product. This understanding is paramount as nasal allergic symptoms may arise during anaphylactic episodes, emphasizing the necessity for effective epinephrine absorption.
Technical Insights on OX640
OX640 is based on Orexo's proprietary delivery platform, AmorphOX, which has shown significant promise in previous studies. This unique technology ensures rapid absorption of drugs via nasal administration while maintaining excellent physical and chemical stability of the medication. Therefore, OX640 stands apart by allowing for flexible storage and ease of use, presenting a needle-free option for patients.
Expert Insight and Future Directions
Robert Rönn, the Senior Vice President and Head of Research and Development at Orexo, emphasized the urgent need for effective treatment options for anaphylaxis, stating, "The performance of OX640 under allergic rhinitis conditions has gained attention from healthcare providers and potential partners. This study addresses essential developmental and regulatory requirements and signifies a crucial step toward gaining regulatory approval." Orexo aims to meet the growing demand for effective allergy management solutions.
Financial Considerations and Company Overview
The financial commitment for this study is projected at approximately SEK 11 million, primarily to be accounted for in the ongoing fiscal year. Orexo continues to focus on providing innovative treatment alternatives, backed by years of expertise in drug formulation technology that meets significant medical needs. With net sales reaching SEK 624 million in the prior fiscal year, Orexo is well-positioned in the pharmaceutical market.
About Orexo
Founded in Sweden, Orexo leverages over three decades of experience in creating improved pharmaceuticals. Their current offerings cater to patients dealing with opioid use disorder and related health challenges. Additionally, Orexo develops and markets products across various therapeutic areas, aligning with leading global partners to ensure wide accessibility to their innovations.
Frequently Asked Questions
What is OX640?
OX640 is an intranasal rescue medication designed to treat severe allergic reactions, including anaphylaxis, using powder-based epinephrine.
How does the AmorphOX platform work?
The AmorphOX platform allows for the quick absorption of medication through nasal delivery, ensuring stability and efficacy in treatment.
Who is conducting the study on OX640?
The study is being conducted by Orexo AB, focusing on evaluating the efficacy of OX640 in participants with allergic rhinitis.
What are the expected outcomes of the study?
The study aims to understand the absorption rates of epinephrine from OX640 under conditions of nasal allergic symptoms, which are critical during anaphylaxis.
How can I learn more about Orexo and its products?
For additional information about Orexo and its developments, you can visit their official website and follow them on various social media platforms.
